Immuron Ltd ADR

Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases and gut-mediated conditions. Its proprietary platform technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine colostrum, which can withstand the acidic environment of the stomach and remain active in the gastrointestinal tract. The company's commercial product, Travelan, is an oral passive immunotherapy that reduces the likelihood of travelers' diarrhea caused by pathogenic bacteria. Travelan is sold as a listed medicine in Australia, a licensed natural health product in Canada, and a dietary supplement in the United States. Immuron also distributes ProIBS, a medical device for IBS symptom treatment, under an exclusive agreement with Calmino Group AB for Australia, New Zealand, and (as of September 2026) the United States. The company's clinical pipeline includes IMM-124E (the active ingredient in Travelan, eligible for an end-of-Phase 2 FDA meeting for travelers' diarrhea) and IMM-529, a first-in-class triple-action biologic targeting Clostridioides difficile infection with FDA IND approval for Phase 2 trials. Immuron is pursuing a partnering strategy for both clinical assets to fund development through licensing arrangements while focusing its internal resources on growing OTC product sales and achieving profitability. Updated Oct 28, 2026